Aducanumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Aducanumab?
Monoclonal antibody
Source Human
Target Beta-amyloid
Clinical data
Identifiers
1384260-65-4
None
Chemical data
Formula C6472H10028N1740O2014S46
145.9 kDa

Aducanumab is a human monoclonal antibody designed for the treatment of Alzheimer’s disease (AD).[1] It is under development by Biogen. It targets aggregated forms of beta amyloid including soluble oligomers and insoluble fibrils deposited into the amyloid plaque found in the brain of AD patients.[medical citation needed]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Aducanumab, American Medical Association